International Journal of Cardiology
Volume 131, Issue 3 , Pages 430-432 , 24 January 2009

Eptifibatide overdose

  • Sagun Parakh

      Affiliations

    • Department of Medicine, James Cook Hospital, Middlesbrough, United Kingdom
    • ,
  • Nimesh Naik

      Affiliations

    • St. Vincent Charity Hospital, Case Western Reserve University, Cleveland, OH, USA
    • ,
  • Nidhi Rohatgi

      Affiliations

    • St. Vincent Charity Hospital, Case Western Reserve University, Cleveland, OH, USA
    • ,
  • Utsav Bhat

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Kapil Parakh

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • Corresponding Author InformationCorresponding author. Department of Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue Baltimore, Maryland 21224-2780, USA. Tel.: +1 410 550 5018; fax: +1 410 550 2972.

Received 16 June 2007 ,Accepted 7 July 2007.

References 

  1. Sheikh A, Baig K. An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards. Cardiovasc Revasc Med. 2006 Oct-Dec;7(4):237–239
  2. Dauerman HL, Frederick PD, Miller D, French WJ. for the National Registry of Myocardial Infarction-5 Investigators. Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron Artery Dis. 2007 Mar;18(2):141–148
  3. Joint Formulary Committee . British national formulary. 53rd ed.. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2007;
  4. MicromedexÒ healthcare series [internet database]. [homepage on the Internet]. Updated periodically. Available from: http://www.micromedex.com/.
  5. Integrilin 2 mg/ml solution for injection [homepage on the Internet]. Available from: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=15630.
  6. Integrilin (r) (eptifibatide) injection for intravenous administration [homepage on the Internet]. Available from: http://www.spfiles.com/piintegrilin.pdf.
  7. Medicines online services [homepage on the Internet]. Available from: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=342.
  8. EudraPharm database [homepage on the Internet]. Available from: http://www.emea.europa.eu/.
  9. ToxbaseÒ (Poisons information). Available from: http://www.toxbase.co.uk/.
  10. Center for drug evaluation and research [homepage on the Internet]. Available from: http://www.fda.gov/cder/index.html.
  11. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998 Aug 13;339(7):436–443
  12. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet. 1997 May 17;349(9063):1422–1428
  13. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: a randomized controlled trial. JAMA. 2001 May 16;285(19):2468–2473
  14. Qureshi AI, Siddiqui AM, Hanel RA, et al. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry. Neurosurgery. 2004 Feb;54(2):307,16;discussion 316-7
  15. Onitilo AA. Delayed profound thrombocytopenia associated with eptifibatide. Am J Hematol. 2006 Dec;81(12):984
  16. Jaffe R, Halon DA, Carmeli J, Lewis BS. Prolonged intravenous eptifibatide infusion for prevention of coronary stent thrombosis. Int J Cardiol. 2007 Jan 18;114(3):409–411
  17. Adverse drug reactions online information tracking drug analysis print eptifibatide. Available from: http://www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_1152181459064.pdf.
  18. Brown DL. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart. 2003 May;89(5):535–537
  19. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2004;43(14):963–981
  20. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000 Feb;139(2 Pt 2):S38–S45
  21. Cheng DK, Jackevicius CA, Seidelin P, Feindel C, Rouleau JL. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery. Can J Cardiol. 2004 Feb;20(2):223–228
  22. Safety related drug labeling changes — eptifibatide [homepage on the Internet]. Available from: http://www.fda.gov/medwatch/safety/1999/jul99.htm#integr.
  23. Sperling RT, Pinto DS, Ho KK, Carrozza JP. Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Catheter Cardiovasc Interv. 2003 Aug;59(4):459–462
  24. Curran MP, Keating GM. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs. 2005;65(14):2009–2035
  25. Kirtane AJ, Piazza G, Murphy SA, et al. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006 Jun 20;47(12):2374–2379
  26. Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006 Sep 26;114(13):1380–1387
  27. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 Jan 19;359(9302):189–198
  28. Fernandes LS, Tcheng JE, O'Shea JC, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol. 2002 Sep 18;40(6):1085–1091
  29. Chew DP, Lincoff AM, Gurm H, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol. 2005 Mar 1;95(5):581–585
  30. Rasty S, Borzak S, Tisdale JE. Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors. J Clin Pharmacol. 2002 Dec;42(12):1366–1373
  31. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. IMPACT investigators. Circulation. 1995 Apr 15;91(8):2151–2157
  32. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation. 1996 Nov 1;94(9):2083–2089
  33. Memon MA, Blankenship JC, Wood GC, Frey CM, Menapace FJ. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med. 2000 Aug 15;109(3):213–217
  34. Orford JL, Fasseas P, Holmes DR, Berger PB. Alveolar hemorrhage associated with periprocedural eptifibatide administration. J Invasive Cardiol. 2004 Jun;16(6):341–342
  35. Iskandar SB, Kasasbeh ES, Mechleb BK, et al. Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors. J Interv Cardiol. 2006 Aug;19(4):356–363
  36. Ali A, Hashem M, Rosman HS, Kazmouz G, Gardin JM, Schrieber TL. Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage. J Invasive Cardiol. 2003 Apr;15(4):186–188
  37. Epelman S, Nair D, Downey R, Militello M, Askari AT. Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis. 2006 Oct;22(2):151–154
  38. Reiter RA, Mayr F, Blazicek H, et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood. 2003 Dec 15;102(13):4594–4599
  39. Reiter R, Jilma-Stohlawetz P, Horvath M, Jilma B. Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide. Transfusion. 2005 Mar;45(3):420–426

PII: S0167-5273(07)01728-7

doi: 10.1016/j.ijcard.2007.07.132

International Journal of Cardiology
Volume 131, Issue 3 , Pages 430-432 , 24 January 2009

Article Tools